Literature DB >> 22895530

microRNAs and thyroid cancer: biological and clinical significance (Review).

Giulia Costanza Leonardi1, Saverio Candido, Maurizio Carbone, Valeria Colaianni, Sebastiano F Garozzo, Diana Cinà, Massimo Libra.   

Abstract

Despite recent advances in the management of thyroid cancer, the survival rate of this tumor may still be improved. Therefore, the identification of biological and molecular features of indolent and aggressive disease would be critical to define clinically useful predictors of high-risk lesions. microRNAs (miRNAs) are small RNA molecules with regulatory function and marked tissue specificity that modulate multiple targets belonging to several pathways. They are frequently deregulated in cancer and constitute a new class of blood-based biomarkers useful for cancer detection and prognosis definition, including thyroid cancer. In this review, the role of miRNAs in thyroid cancer development is described. The most common miRNAs detected in thyroid cancer along with their clinical significance are also discussed. Further studies aimed to detect plasma-based miRNA biomarkers in thyroid cancer patients may provide further insight into the management of thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22895530     DOI: 10.3892/ijmm.2012.1089

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  15 in total

1.  Identification of miR-7 as an oncogene in renal cell carcinoma.

Authors:  Zuhu Yu; Liangchao Ni; Duqun Chen; Qiang Zhang; Zhengming Su; Yadong Wang; Wenshui Yu; Xionghui Wu; Jiongxian Ye; Shangqi Yang; Yongqing Lai; Xianxin Li
Journal:  J Mol Histol       Date:  2013-06-21       Impact factor: 2.611

Review 2.  MicroRNA aberrations: An emerging field for gallbladder cancer management.

Authors:  Vishal Chandra; Jong Joo Kim; Balraj Mittal; Rajani Rai
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

3.  MicroRNA-338-3p inhibits thyroid cancer progression through targeting AKT3.

Authors:  Guo-Qing Sui; Dan Fei; Feng Guo; Xi Zhen; Qiang Luo; Shuai Yin; Hui Wang
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

4.  Loss of MTUS1 Expression Is Associated With Poor Prognosis in Patients With Gallbladder Carcinoma.

Authors:  Jongmin Sim; Yeseul Kim; Hyungsung Kim; Seongsik Bang; Seungyun Jee; Seongun Park; Su-Jin Shin; Kiseok Jang
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

Review 5.  Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy.

Authors:  Jinwei Hu; Isabella J Yuan; Saied Mirshahidi; Alfred Simental; Steve C Lee; Xiangpeng Yuan
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 5.923

6.  MicroRNA-497 inhibits thyroid cancer tumor growth and invasion by suppressing BDNF.

Authors:  Peisong Wang; Xianying Meng; Yan Huang; Zhi Lv; Jia Liu; Guimin Wang; Wei Meng; Shuai Xue; Qiang Zhang; Pengju Zhang; Guang Chen
Journal:  Oncotarget       Date:  2017-01-10

7.  Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer.

Authors:  Luca Falzone; Saverio Candido; Rossella Salemi; Maria S Basile; Aurora Scalisi; James A McCubrey; Francesco Torino; Salvatore S Signorelli; Maurizio Montella; Massimo Libra
Journal:  Oncotarget       Date:  2016-11-08

8.  Predictive factors of contralateral occult carcinoma in patients with papillary thyroid carcinoma: a retrospective study.

Authors:  Xiaohang Chen; Zhenwei Zhong; Muye Song; Jiru Yuan; Ziyang Huang; Jialin Du; Yongchen Liu; Zeyu Wu
Journal:  Gland Surg       Date:  2020-08

Review 9.  The Role of miRNA in Papillary Thyroid Cancer in the Context of miRNA Let-7 Family.

Authors:  Ewelina Perdas; Robert Stawski; Dariusz Nowak; Maria Zubrzycka
Journal:  Int J Mol Sci       Date:  2016-06-15       Impact factor: 5.923

Review 10.  MiR-137: an important player in neural development and neoplastic transformation.

Authors:  E Mahmoudi; M J Cairns
Journal:  Mol Psychiatry       Date:  2016-09-13       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.